REPL (Replimune Group) YoY EPS Growth: 24.21% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

REPL Replimune Group Inc REPL
27 GF Score
Price $14.71
! 4 Warning Signs
View Full Analysis

What is Replimune Group YoY EPS Growth?

Replimune Group REPL -0.27% 27 YoY EPS Growth is 24.21% as of Jun. 2026. GuruFocus rates REPL with a GF Score™ of 27/100. The stock has 4 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Replimune Group's YoY EPS Growth for the quarter that ended in Jun. 2026 was 24.21%.

Replimune Group's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was $-0.72.

Replimune Group YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Replimune Group's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Replimune Group YoY EPS Growth Chart

Replimune Group Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -29.14 -32.30 -8.36 5.25 -10.10

Replimune Group Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.79 -32.35 2.53 7.32 24.21
REPL
27GF Score
Replimune Group Inc REPL
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Replimune Group YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Replimune Group's YoY EPS Growth for the fiscal year that ended in Mar. 2026 is calculated as:

YoY EPS Growth (A: Mar. 2026 )
=(Earnings per Share (Diluted) (A: Mar. 2026 )-Earnings per Share (Diluted) (A: Mar. 2025 ))/ | Earnings per Share (Diluted) (A: Mar. 2025 ) |
=(-3.38--3.07)/ | -3.07 |
=-10.10 %

Replimune Group's YoY EPS Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EPS Growth (Q: Jun. 2026 )
=(Earnings per Share (Diluted) (Q: Jun. 2026 )-Earnings per Share (Diluted) (Q: Jun. 2025 )) / | Earnings per Share (Diluted) (Q: Jun. 2025 )) |
=(-0.72--0.95)/ | -0.95 |
=24.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 24.21% mean?
Replimune Group (REPL) has a YoY EPS Growth of 24.21% as of Jun. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Replimune Group and its competitors.
Is Replimune Group's YoY EPS Growth too high?
Replimune Group's current YoY EPS Growth is 24.21%. Overall, Replimune Group has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Replimune Group's YoY EPS Growth compare to ANNX and SLDB?
Replimune Group's YoY EPS Growth of 24.21% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Replimune Group and its competitors. Replimune Group's current YoY EPS Growth is 24.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Replimune Group stock overvalued right now?
Replimune Group (REPL) has a current YoY EPS Growth of 24.21%. The current YoY EPS Growth is 24.21%. Replimune Group's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Replimune Group (REPL), the current YoY EPS Growth is 24.21% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Replimune Group Business Description

Other Exchanges 7R8:Germany
Address 500 Unicorn Park Drive, Suite 303, 3rd Floor, Woburn, MA, USA, 01801
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
27GF Score

Get the complete analysis for REPL

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.71
Price